Puma Biotechnology Inc (PBYI) News

Puma Biotechnology Inc (PBYI): $4.10

0.39 (-8.69%)

POWR Rating

Component Grades








Add PBYI to Watchlist
Sign Up

Industry: Biotech




#11 of 339

in industry

Filter PBYI News Items

PBYI News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

PBYI News Highlights

  • For PBYI, its 30 day story count is now at 12.
  • Over the past 26 days, the trend for PBYI's stories per day has been choppy and unclear. It has oscillated between 1 and 3.
  • AL, BEAT and CM are the most mentioned tickers in articles about PBYI.

Latest PBYI News From Around the Web

Below are the latest news stories about PUMA BIOTECHNOLOGY INC that investors may wish to consider to help them evaluate PBYI as an investment opportunity.

Freeline (FRLN) Shares Rise on Merger Agreement With Syncona

Freeline Therapeutics (FRLN) is set to be acquired by Syncona Ltd. The transaction is expected to be closed in the first quarter of 2024. Shares rise.

Yahoo | November 23, 2023

Immix (IMMX) CAR-T Therapy IND Cleared by FDA, Stock Down

The FDA clears Immix's (IMMX) investigational new drug application for BCMA CAR-T cell therapy, NXC-201, to expand clinical studies in relapsed/refractory AL amyloidosis to the United States. Stock falls.

Yahoo | November 22, 2023

Here's Why You May Invest in Puma Biotechnology (PBYI) Stock

Here, we discuss some reasons why investing in Puma Biotechnology (PBYI) stock now may turn out to be a more prudent move than ever.

Yahoo | November 20, 2023

Read This Before Judging Puma Biotechnology, Inc.'s (NASDAQ:PBYI) ROE

One of the best investments we can make is in our own knowledge and skill set. With that in mind, this article will...

Yahoo | November 18, 2023

Chemomab (CMMB) Up on Fast Track Designation to CM-101 for PSC

The FDA bestows Fast Track designation to Chemomab's (CMMB) pipeline candidate, CM-101, for the treatment of primary sclerosing cholangitis. Stock rises.

Yahoo | November 16, 2023

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

LOS ANGELES, November 06, 2023--Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on November 1, 2023, the Compensation Committee of Puma’s Board of Directors approved the grant of an inducement restricted stock unit award covering 15,000 shares of Puma common stock to one new non-executive employee.

Yahoo | November 6, 2023

Puma Biotech (PBYI) Q3 Earnings Beat, Revenues Lag Estimates

Puma Biotech's (PBYI) third-quarter 2023 earnings beat estimates, while revenues miss the same. The company tightens the full-year revenue guidance.

Yahoo | November 3, 2023

Q3 2023 Puma Biotechnology Inc Earnings Call

Q3 2023 Puma Biotechnology Inc Earnings Call

Yahoo | November 3, 2023

Puma Biotechnology, Inc. (NASDAQ:PBYI) Q3 2023 Earnings Call Transcript

Puma Biotechnology, Inc. (NASDAQ:PBYI) Q3 2023 Earnings Call Transcript November 2, 2023 Puma Biotechnology, Inc. misses on earnings expectations. Reported EPS is $0.12 EPS, expectations were $0.15. Operator: Good afternoon. My name is Camilla, and I will be your conference call operator today. [Operator Instructions] As a reminder, this call is being recorded. I would […]

Yahoo | November 3, 2023

Puma Biotechnology Inc (PBYI) Reports Positive Net Income and Cash Flow in Q3 2023

Company's product revenue for the first nine months of 2023 reaches $149.9 million

Yahoo | November 2, 2023

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!